Literature DB >> 12035031

Trends in long-term survival following liver resection for hepatic colorectal metastases.

Michael A Choti1, James V Sitzmann, Marcelo F Tiburi, Wuthi Sumetchotimetha, Ram Rangsin, Richard D Schulick, Keith D Lillemoe, Charles J Yeo, John L Cameron.   

Abstract

OBJECTIVE: To examine trends in outcomes of patients undergoing resection at a single tertiary care referral center over a 16-year period. SUMMARY BACKGROUND DATA: Hepatic resection is considered the treatment of choice in selected patients with colorectal metastasis confined to the liver. Although a variety of retrospective studies have demonstrated improvements in short-term outcomes in recent years, changes in long-term survival over time are less well-established.
METHODS: Data from 226 consecutive patients undergoing potentially curative liver resection for colorectal metastases between 1984 and 1999 were analyzed. Actuarial survival rates related to prognostic determinants were analyzed using the log-rank test.
RESULTS: The median survival for the entire cohort was 46 months, with 5- and 10-year survival rates of 40% and 26% respectively. Ninety-three patients operated on between 1984 and 1992 were found to have an overall survival of 31% at 5 years, compared to 58% for the 133 patients operated on during the more recent period (1993-1999). Both overall and disease-free survival were significantly better in the recent time period compared with the earlier period on both univariate and multivariate analyses. Other independent factors associated with improved survival included number of metastatic tumors < or = 3, negative resection margin, and CEA < 100. Comparisons were made between time periods for a variety of patient, tumor and treatment-related factors. Among all parameters studied, only resection type (anatomical versus nonanatomical), use of intraoperative ultrasonography, and perioperative chemotherapy administration differed between the early and recent time periods.
CONCLUSIONS: Long-term survival following liver resection for colorectal metastases has improved significantly in recent years at our institution. Although the reasons for this survival trend are not clear, contributing factors may include the use of newer preoperative and intraoperative imaging, increased use of chemotherapy, and salvage surgical therapy.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12035031      PMCID: PMC1422504          DOI: 10.1097/00000658-200206000-00002

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  22 in total

1.  Resection of the liver for colorectal carcinoma metastases. A multi-institutional study of long-term survivors.

Authors:  K S Hughes; R B Rosenstein; S Songhorabodi; M A Adson; D M Ilstrup; J G Fortner; B J Maclean; J H Foster; J M Daly; D Fitzherbert
Journal:  Dis Colon Rectum       Date:  1988-01       Impact factor: 4.585

Review 2.  Resection of colorectal liver metastases revisited.

Authors:  J Scheele; C Rudroff; A Altendorf-Hofmann
Journal:  J Gastrointest Surg       Date:  1997 Sep-Oct       Impact factor: 3.452

3.  Survival of patients evaluated by FDG-PET before hepatic resection for metastatic colorectal carcinoma: a prospective database study.

Authors:  S M Strasberg; F Dehdashti; B A Siegel; J A Drebin; D Linehan
Journal:  Ann Surg       Date:  2001-03       Impact factor: 12.969

Review 4.  Surgical management of hepatic metastases from colorectal malignancies.

Authors:  R Malafosse; C Penna; A Sa Cunha; B Nordlinger
Journal:  Ann Oncol       Date:  2001-07       Impact factor: 32.976

5.  Intraoperative ultrasound (IOUS) is essential in the management of metastatic colorectal liver lesions.

Authors:  A Cervone; A Sardi; G L Conaway
Journal:  Am Surg       Date:  2000-07       Impact factor: 0.688

6.  [Resection of colorectal liver metastases. What prognostic factors determine patient selection?].

Authors:  J Scheele; A Altendorf-Hofmann; T Grube; W Hohenberger; R Stangl; K Schmidt
Journal:  Chirurg       Date:  2001-05       Impact factor: 0.955

7.  Resection of hepatic metastases from colorectal cancer.

Authors:  M A Adson; J A van Heerden; M H Adson; J S Wagner; D M Ilstrup
Journal:  Arch Surg       Date:  1984-06

8.  Survival benefit of repeat liver resections for recurrent colorectal metastases: 143 cases. Association Francaise de Chirurgie.

Authors:  B Nordlinger; J C Vaillant; M Guiguet; P Balladur; F Paris; P Bachellier; D Jaeck
Journal:  J Clin Oncol       Date:  1994-07       Impact factor: 44.544

9.  Resection of liver metastases in colorectal cancer--competitive analysis of treatment results in synchronous versus metachronous metastases.

Authors:  P Schlag; P Hohenberger; C Herfarth
Journal:  Eur J Surg Oncol       Date:  1990-08       Impact factor: 4.424

10.  Perioperative blood transfusion and determinants of survival after liver resection for metastatic colorectal carcinoma.

Authors:  C B Rosen; D M Nagorney; H F Taswell; S L Helgeson; D M Ilstrup; J A van Heerden; M A Adson
Journal:  Ann Surg       Date:  1992-10       Impact factor: 12.969

View more
  429 in total

1.  Radiofrequency ablation for colorectal liver metastases: prognostic factors in non-surgical candidates.

Authors:  Ayumi Hamada; Koichiro Yamakado; Atsuhiro Nakatsuka; Junji Uraki; Masataka Kashima; Haruyuki Takaki; Takashi Yamanaka; Yasuhiro Inoue; Masato Kusunoki; Kan Takeda
Journal:  Jpn J Radiol       Date:  2012-06-05       Impact factor: 2.374

Review 2.  The surgical treatment of patients with colorectal cancer and liver metastases in the setting of the "liver first" approach.

Authors:  Leonardo Patrlj; Mario Kopljar; Robert Kliček; Masa Hrelec Patrlj; Marijan Kolovrat; Mislav Rakić; Antonija Duzel
Journal:  Hepatobiliary Surg Nutr       Date:  2014-10       Impact factor: 7.293

3.  Clinical risk score can be used to select patients for staging laparoscopy and laparoscopic ultrasound for colorectal liver metastases.

Authors:  A J Shah; J Phull; M D Finch-Jones
Journal:  World J Surg       Date:  2010-09       Impact factor: 3.352

Review 4.  The surgical treatment of hepatic metastases in colorectal carcinoma.

Authors:  Ulf Peter Neumann; Daniel Seehofer; Peter Neuhaus
Journal:  Dtsch Arztebl Int       Date:  2010-05-14       Impact factor: 5.594

5.  Percutaneous stereotactic radiofrequency ablation of colorectal liver metastases.

Authors:  Reto Bale; Gerlig Widmann; Peter Schullian; Marion Haidu; Georg Pall; Alexander Klaus; Helmut Weiss; Matthias Biebl; Raimund Margreiter
Journal:  Eur Radiol       Date:  2011-11-10       Impact factor: 5.315

6.  CT-guided radiofrequency ablation as a salvage treatment of colorectal cancer hepatic metastases developing after hepatectomy.

Authors:  Constantinos T Sofocleous; Elena N Petre; Mithat Gonen; Karen T Brown; Stephen B Solomon; Anne M Covey; William Alago; Lynn A Brody; Raymond H Thornton; Michael D'Angelica; Yuman Fong; Nancy E Kemeny
Journal:  J Vasc Interv Radiol       Date:  2011-04-22       Impact factor: 3.464

Review 7.  Current treatment for colorectal liver metastases.

Authors:  Evangelos P Misiakos; Nikolaos P Karidis; Gregory Kouraklis
Journal:  World J Gastroenterol       Date:  2011-09-28       Impact factor: 5.742

8.  Analysis of preoperative prognostic factors for long-term survival after hepatic resection of liver metastasis of colorectal carcinoma.

Authors:  Atsushi Sasaki; Yukio Iwashita; Kohei Shibata; Toshifumi Matsumoto; Masayuki Ohta; Seigo Kitano
Journal:  J Gastrointest Surg       Date:  2005-03       Impact factor: 3.452

9.  Conditional Recurrence-Free Survival after Resection of Colorectal Liver Metastases: Persistent Deleterious Association with RAS and TP53 Co-Mutation.

Authors:  Yoshikuni Kawaguchi; Heather A Lillemoe; Elena Panettieri; Yun Shin Chun; Ching-Wei D Tzeng; Thomas A Aloia; Scott Kopetz; Jean-Nicolas Vauthey
Journal:  J Am Coll Surg       Date:  2019-05-02       Impact factor: 6.113

10.  Superiority of combined chemo-embolization and portal infusion with 5-fluorouracil over locoregional infusion concepts in Novikoff hepatoma-bearing rats.

Authors:  Hermann Bödeker; Ernst-Jan Kamphorst; Peter H Wünsch; Ulrich Linnemann; Martin R Berger
Journal:  J Cancer Res Clin Oncol       Date:  2003-09-26       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.